PharmaNutra at the NATA Symposium 2019 for the third consecutive year

Last week PharmaNutra attended the NATA Symposium 2019, the twentieth edition of the most important European event dedicated to transfusion medicine

The Maritim proArte Hotel in Berlin hosted the 20th edition of the NATA Symposium, the most important European event dedicated to transfusion medicine, on 4 and 5 April.

Also this year the scientific program of NATA was focused on the developments of scientific research on topics such as anemia, Patient Blood Management (management optimization of blood resource) and thrombosis.

PharmaNutra SpA, leader in the marketing of oral iron, thanks to the SiderAL® product line, based on Sucrosomial® iron, was present at NATA for the third year in a row with its own stand, coordinated by the Head of the Scientific Department, Dr. Germano Tarantino. A presence that has been noticed, in a context that has seen a greater and increasingly international participation of doctors compared to previous years who have been strongly interested in SiderAL® products, the only oral iron on display at the NATA Symposium 2019.

SiderAL® was also the main topic of a speech by Professor Manuel Muñoz, transfusion medicine expert of the Department of Surgery, Biochemistry and Immunology of the University of Malaga and member of the NATA Board of Directors, in his follow-up reading about innovative iron oral solutions. In his focus, Professor Muñoz quoted the latest discoveries about Sucrosomial® Iron, starting with the review published last October in the periodical Pharmaceuticals entitled “Sucrosomial® Iron: a new generation iron for improving oral supplementation”, highlighting how SiderAL® can really be considered the new generation among the various oral irons products currently on the market.

“It was a very successful edition of the NATA and at our stand we had really a lot of turnout, before and after Professor Muñoz reading,” said Dr. Tarantino. “SiderAL® is a product that is well known and appreciated all over the world, a revolution that begins to have truly international dimensions. ”At the moment”, continues Tarantino, ”we have four studies in progress about Patient Blood Management, from which we expect excellent feedback after seeing the preliminary datas. PBM is a topic that remains fundamental for us, to make available to patients an oral iron that has an increasingly greater tolerability and bioavailability ”.